Key Takeaways Ocugen dosed the first patient in the pivotal phase III ArMaDa3 study for geographic atrophy.OCU410's phase III study will enroll 237 patients and assess lesion growth and functional vision.Ocugen expects to file a BLA for OCU410 in 2028, with Europe discussions also underway. Ocugen (OCGN - Free Report) announced that it has dosed the first patient in the global phase III ArMaDa3 study evaluating the modifier gene therapy candidate, OCU410, for treating geographic atrophy (“GA”) secondary to dry age-related macular degeneration (dAMD).
The initiation of the phase III study follows a Type B End-of-phase II meeting with the FDA's Center for Biologics Evaluation and Research in July 2026. Per management, the meeting resulted in alignment on key phase III design elements, including the primary and secondary endpoints, dose, adaptive design and a single pivotal study pathway intended to support a biologics license application (“BLA”) for OCU410.
The randomized, phase III registrational study, which also happens to be the first pivotal gene therapy study in GA, will enroll 237 patients with GA secondary to dAMD. Patients will be randomized 2:1 to receive a single 200 µL subretinal injection of OCU410 at a dose of 5×10^10 vg/mL or remain in an untreated control arm. The primary endpoint of the study is to check the rate of change in square root-transformed GA lesion area through month 12 using fundus autofluorescence.
Secondary endpoints will evaluate functional vision, including the proportion of patients experiencing a loss of at least 15 ETDRS letters in low-luminance visual acuity, as well as the rate of change in ellipsoid zone area loss.
OCGN Price PerformanceYear to date, shares of Ocugen have declined 1.5% against the industry’s 9.7% increase.
Image Source: Zacks Investment Research
OCGN’s Recent Developments With OCU410In July 2026, the FDA granted a Regenerative Medicine Advanced Therapy (“RMAT”) designation to OCU410 for the treatment of GA secondary to dAMD.
The RMAT designation provides OCU410 with eligibility for accelerated approval and priority review, along with benefits associated with Breakthrough Therapy designation. It also enables enhanced and frequent interactions with the FDA during the development process.
Both the phase III study and the FDA’s RMAT designation are based on 12-month data from the phase II ArMaDa study, which evaluated OCU410 in patients with GA secondary to dAMD. Data from the same showed a statistically significant 31% reduction in lesion growth compared with control at the intended medium dose, along with 27% ellipsoid zone preservation versus control.
In addition, approximately 20% of patients in the medium-dose group showed no disease progression, while 75% experienced more than a 30% reduction in lesion growth at 12 months. No treatment-related adverse side effects were reported either.
Ocugen expects to file a BLA for OCU410 in 2028. The company is also in discussions with the European Medicines Agency regarding alignment that could potentially allow the single phase III study to support a marketing authorization application for OCU410 in Europe.
OCGN’s Zacks Rank & Stocks to ConsiderOcugen currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) , Anika Therapeutics (ANIK - Free Report) and Precigen (PGEN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 3.8% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 earnings per share have risen from 41 cents to $1.05, while estimates for 2027 have increased from 46 cents to 95 cents during the same time. ANIK’s shares have surged 119.7% year to date.
Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.
Over the past 60 days, Precigen’s estimates for 2026 have moved from a loss of 2 cents per share to earnings of 25 cents, while estimates for 2027 have increased from 25 cents to 86 cents during the same time. PGEN’s shares have rallied 64.2% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 108.96%.
The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation, providing enhanced agency engagement throughout development and eligibility for accelerated approval and priority reviewPhase 3 design fully aligned with FDA; Biologics License Application (BLA) filing anticipated in 2028OCU410 is designed as a one-time subretinal gene therapy that addresses multiple disease pathways, offering a differentiated approach from approved complement inhibitors in the U.S. which address individual disease pathways and require ongoing intravitreal injections MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway for the program.
“Dosing the first patient in our global Phase 3 trial, just weeks after receiving RMAT designation, marks a defining moment for the OCU410 program – and for the millions of people living with geographic atrophy. Outside the U.S., there are currently no approved treatments for GA, while in the U.S., available treatment options address only one of the four disease pathways and require ongoing, repeated eye injections,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. “This is our third modifier gene therapy program to advance into late-stage development, demonstrating the strength of our platform and our vision for potentially delivering a one-time treatment for life.”
The initiation of dosing follows the successful completion of a Type B End-of-Phase 2 (EOP2) meeting with FDA’s Center for Biologics Evaluation and Research (CBER) in July 2026, resulting in alignment on all critical Phase 3 design elements, including primary and secondary endpoints, dose, adaptive design, and a single pivotal trial pathway to support a BLA.
“We are entering a global single Phase 3 with a well-defined program: a dose validated in a randomized, controlled Phase 2 study; an FDA-endorsed primary endpoint measuring the rate of lesion growth; and a secondary endpoint assessing functional vision,” said Mohamed Genead, MD, Chief Medical Officer of Ocugen. “The Phase 3 program builds on compelling 12-month Phase 2 data, which demonstrated a statistically significant 31% reduction in lesion growth with the optimal dose compared with control following a single subretinal injection, along with concordant preservation of the ellipsoid zone and no drug-related serious adverse events (SAEs) or adverse events of special interest (AESIs).”
OCU410 delivers the human retinoid-related orphan receptor alpha (RORA) modifier gene via a single subretinal injection of an AAV5 vector. Unlike therapies targeting a single pathway, OCU410 is designed to simultaneously address multiple pathophysiological drivers of GA-complement overactivation, chronic inflammation, oxidative stress, and lipid dysregulation. GA affects approximately 2–3 million people in the U.S. and Europe and is a leading cause of irreversible central vision loss in older adults, with prevalence expected to rise as the population ages.
According to study investigator Victor Gonzalez, MD, “Patients with geographic atrophy continue to face irreversible structural and functional loss of the retina, along with limited treatment options. The OCU410 Phase 3 study provides an important opportunity to evaluate a novel, potential one-time gene therapy approach that could lessen the burden of current treatments in the U.S., which require patients to undergo multiple injections every year.”
Global Phase 3 Registrational Trial Design
The Phase 3 trial is a global, multicenter, randomized, controlled study enrolling 237 subjects with GA secondary to dAMD, randomized 2:1 to a single 200 µL subretinal injection of OCU410 (5×1010 vg/mL) or an untreated control arm, with sites in the United States, Canada, Europe, and Latin America.
Primary endpoint: Rate of change of square root-transformed GA lesion area (√mm²/year) by fundus autofluorescence (FAF) at baseline, Month 4, Month 8, and Month 12, analyzed by MMRM.Secondary endpoints: Proportion of subjects with Low-Luminance Visual Acuity (LLVA) loss ≥15 ETDRS letters at two consecutive visits through Month 12, providing a functional vision anchor to the primary anatomic endpoint; and rate of change of ellipsoid zone (EZ) area loss by SD-OCT.Regulatory path: A single, adequate and well-controlled Phase 3 trial, aligned with FDA feedback, is intended to support a BLA filing anticipated in 2028. Discussions are ongoing with the European Medicines Agency (EMA) regarding alignment to potentially support a marketing authorization application (MAA) in Europe with this single Phase 3 trial.
RMAT Designation: Regulatory and Strategic Significance
On July 29, 2026, FDA granted RMAT designation to OCU410 based on Phase 2 clinical data demonstrating clinically meaningful efficacy and a favorable safety profile, with no serious adverse events related to OCU410 reported. RMAT designation is granted to regenerative medicine therapies intended to treat serious or life-threatening conditions where preliminary clinical evidence indicates the potential to address an unmet medical need.
For the OCU410 program, RMAT designation provides:
Eligibility for accelerated approval and priority review, which may compress the time from BLA submission to potential market entry.All benefits of Breakthrough Therapy designation, including intensive FDA guidance on efficient development and organizational commitment involving senior FDA leadership.Early and frequent FDA interactions on the use of surrogate and intermediate clinical endpoints reasonably likely to predict long-term clinical benefit-directly relevant to OCU410’s FAF-based anatomic primary endpoint.Potential flexibility in satisfying post-approval requirements, including through expanded patient registries or real-world evidence. Taken together with FDA alignment on the Phase 3 design and the initiation of dosing, RMAT designation further de-risks the regulatory pathway for OCU410 and reinforces the differentiation of a one-time, multi-pathway gene therapy in a GA market currently served only by chronically administered intravitreal complement inhibitors.
Supporting Phase 2 ArMaDa Data
The Phase 3 trial and the RMAT designation are supported by 12-month data from the Phase 2 ArMaDa trial (NCT06018558), a multicenter, randomized, controlled study of 51 subjects with GA secondary to dAMD.
Lesion growth (FAF): 31% reduction in GA lesion area growth rate in the medium dose group versus control at 12 months (p < 0.05) in the pivotal phase 3 population (lesion size of ≥2.5 mm2 and ≤17.5 mm2), a potential 2× treatment benefit relative to the 15% and 22% reductions reported for currently approved therapies in the U.S. at 12 and 24 months, respectively.EZ preservation (SD-OCT): 27% reduction in ellipsoid zone area loss in the medium dose group versus control, a structural correlate of visual function.Responder analysis: In the medium dose group, approximately 20% of treated subjects showed no disease progression; 75% demonstrated >30% reduction in lesion growth at 12 months.Safety: No OCU410-related serious adverse events (SAEs) or adverse events of special interest (AESIs) reported to date. About OCU410
OCU410 (AAV5-hRORA) is Ocugen’s investigational first-in-class modifier gene therapy, delivering the RORA gene via a single unilateral subretinal injection to regulate complement activation, neuroinflammation, oxidative stress, and lipid metabolism – multiple pathways implicated in the pathogenesis of GA. OCU410 has received RMAT designation from the FDA and Advanced Therapy Medicinal Product classification from the European Medicines Agency's Committee for Advanced Therapies.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of enrollment and data readouts, the ability to initiate new clinical programs, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that receipt of RMAT designation may not lead to faster development or accelerated regulatory review or approval; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our annual and quarterly filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026.
Citi 2026 Biopharma Back to School Conference
Location: JW Marriott Essex House, New York City, NY
Date: Wednesday, September 9, 2026
Time: 3:40–4:15 p.m. ET
Format: Fireside Chat
Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen
H.C. Wainwright 28th Annual Global Investment Conference
Location: Lotte New York Palace, New York City, NY
Date: Tuesday, September 15, 2026
Time: 3:00–3:30 p.m. ET
Format: Fireside chat
Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen
The Retina Society 59th Annual Scientific Meeting
Location: Fairmont Century Plaza, Los Angeles, CA
Date: September 24, 2026
Time: 3:15 p.m. PST
Format: Presentation
Title: Safety and Efficacy of Subretinal OCU410 Gene Therapy for Geographic Atrophy: 12-Month Randomized Phase 2 ArMaDa Results
Presenter: Dr. Raj K. Maturi
A webcast of the Citi and H.C. Wainwright presentations will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month
Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar Musunuri said during a Canaccord discussion.
Musunuri said the company is targeting biologics license applications, or BLAs, next year for its retinitis pigmentosa and Stargardt programs, while its geographic atrophy program is expected to follow on a longer timeline. He said the company’s objective is to pursue approvals in major markets, including the U.S., Europe and Japan, and to improve patient access in parallel with regulatory work.
Get Ocugen alerts:
Modifier Gene Therapy Platform
Ocugen’s approach differs from gene-specific therapies by using “modifier genes,” which Musunuri described as genes that regulate networks of functions in retinal cells. The company’s technology originated from work by Dr. Neena Haider at Harvard, according to Musunuri.
For retinitis pigmentosa, Ocugen is developing OCU400, which uses the Nr2e3 modifier gene. Musunuri said Nr2e3 affects phototransduction pathways, which are particularly relevant in retinitis pigmentosa as patients can lose peripheral and night vision before central vision.
For Stargardt disease and geographic atrophy, Ocugen is developing treatments using the RORA modifier gene. Musunuri said RORA is intended to regulate multiple disease-related pathways, including oxidative stress, lipid metabolism, inflammation and the complement system. He said the company believes the therapy may help restore cellular homeostasis and create a healthier environment for retinal cells.
Musunuri said Ocugen’s intellectual property extends beyond ophthalmology into neurological applications, though he characterized that area as a future opportunity.
Stargardt and Geographic Atrophy Programs
OCU410ST, the company’s Stargardt disease candidate, is in a Phase II/III study enrolling patients ages 3 and older, from early through advanced stages of disease. Musunuri said the study was endorsed by the European Medicines Agency and that the FDA allowed Ocugen to convert its Phase II study into a combined Phase II/III trial following a small Phase I study.
The company expects top-line data from the Stargardt study in the second quarter of next year, Musunuri said. Ocugen then plans to file a BLA and pursue market authorization in parallel within several months of the results. If development proceeds according to plan, he said approval and launch could occur in 2028.
Musunuri contrasted the program with oral therapies that may target individual disease pathways and require ongoing dosing. He said Ocugen’s subretinal gene therapy is designed as a one-time administration, while emphasizing that efficacy and safety data will determine its potential differentiation.
OCU410, Ocugen’s geographic atrophy candidate, uses the same RORA construct as OCU410ST but at a different dose, Musunuri said. The geographic atrophy program has received the FDA’s Regenerative Medicine Advanced Therapy, or RMAT, designation. He said the company has received FDA clearance to begin a single Phase III trial and is working with the EMA to align the study as a global trial.
Retinitis Pigmentosa Readout and Filing Plans
Ocugen expects first-quarter top-line data next year from its Phase III trial of OCU400 in retinitis pigmentosa. The study includes 140 patients, uses a 2:1 treatment-to-control ratio and covers more than 30 mutations, according to Musunuri.
The primary assessment uses a mobility test designed to measure patients’ ability to navigate under low-light conditions. Musunuri said the company refined the test with FDA input and also plans to track low-luminance visual acuity as a secondary and longer-term measure. He said the company observed approximately two lines of low-luminance visual acuity improvement in treated eyes among Phase I/II patients over three years.
Musunuri said Ocugen has treated more than 325 patients across its clinical trials and expanded-access program, including more than 200 patients with retinitis pigmentosa. He said the company has not observed serious adverse events related to its gene therapy programs in those populations.
On manufacturing, Musunuri said Ocugen has completed process performance qualification validation runs needed for an OCU400 BLA submission and has commercial-scale material that could be used for supply. The company expects to complete the BLA within months after the Phase III data. Under RMAT, it may be eligible for a rolling submission, although Musunuri said the final clinical module would start the FDA review clock.
Capital Runway and Commercialization
Musunuri said a recently announced $130 million convertible note financing is expected to fund Ocugen into 2028. He said overall spending is not expected to increase substantially next year because recruitment for two Phase III programs was completed this year, while the geographic atrophy study begins.
The company is also evaluating regional partnerships and non-dilutive funding opportunities, particularly outside the U.S., Musunuri said. He said Ocugen intends to remain opportunistic regarding U.S. commercialization and may consider additional equity financing if needed to support a U.S. launch.
About Ocugen (NASDAQ:OCGN)Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.
In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Ocugen Right Now?Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Key Takeaways OCGN reported a wider Q2 loss as higher R&D costs offset a modest revenue beat from collaboration income. Ocugen raised cash, retired higher-interest debt, and extended its cash runway into 2028.OCGN advanced key gene therapy programs, with multiple late-stage data readouts and BLA filings planned. Ocugen (OCGN - Free Report) reported a second-quarter 2026 loss of 7 cents per share, which was wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Higher research and development spending weighed on results.
Revenues rose 8.4% year over year to $1.5 million and slightly beat the Zacks Consensus Estimate of $1.4 million. The company’s top line currently comprises only collaboration revenues.
OCGN’s Costs Climb as Pipeline Spending AdvancesTotal operating expenses increased 18.2% year over year to $17.9 million. Research and development expenses rose 27.2% to $10.7 million, while general and administrative expenses increased 7.0% to $7.2 million.
Cash, cash equivalents and restricted cash totaled $100.4 million as of June 30, 2026, up from $32.2 million as of March 31. The increase followed the closing of $130.0 million of 6.75% convertible senior notes due 2034, which generated about $112.5 million in net proceeds.
Ocugen used about $32.7 million of those proceeds to fully retire its Avenue Capital loan and eliminate 12.25% interest-rate debt. Management expects the financing to extend the cash runway into 2028, supporting the company’s late-stage clinical programs and planned regulatory submissions.
Ocugen’s shares declined 3% on Wednesday after the results were announced. Year to date, shares of OCGN have declined 8.2% compared with the industry’s 3.5% decline.
Image Source: Zacks Investment Research
OCGN’s Pipeline Progress & Clinical UpdatesOcugen is advancing its ophthalmology gene therapy pipeline, targeting three biologics license application (BLA) submissions by 2028. The first half of 2027 is expected to be catalyst-rich, with late-stage top-line data anticipated for OCU400 and OCU410ST.
Enrollment has been completed in a phase III liMeliGhT study on lead modifier gene therapy candidate, OCU400, to treat Retinitis pigmentosa, or RP, a rare genetic disorder that can lead to vision loss and blindness. Top-line data from the phase III study is expected in the first quarter of 2027. Management said the FDA feedback keeps the rolling BLA pathway tied to the top-line data, with completion of the filing targeted for the second quarter of 2027 and potential approval in the fourth quarter as a treatment option for early- to late-stage RP.
OCU410ST is being developed as a one-time gene therapy for the treatment of Stargardt disease, a rare inherited retinal disorder. In April 2026, the company completed enrollment and dosing in the phase II/III GARDian3 pivotal confirmatory study on OCU410ST for Stargardt disease. Management expects an interim outcome decision for the first 50% of subjects at eight months in the third quarter of 2026. Top-line data are anticipated in the second quarter of 2027, with a BLA submission planned for mid-2027.
The FDA cleared the phase III ArMaDa3 registrational study of Ocugen’s another important candidate, OCU410, for geographic atrophy, an advanced stage of dry age-related macular degeneration. Ocugen plans to initiate the global phase III study by September. The program is supported by positive 12-month phase II data showing a statistically significant 31% reduction in geographic atrophy lesion growth at the optimal dose in the target lesion-size population. BLA and Marketing Authorization Application filings are targeted for 2028.
OCGN's Zacks Rank & Stocks to ConsiderOcugen currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) , Harmony Biosciences (HRMY - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 2.7% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.33. Over the same period, EPS estimates for 2027 have surged from $3.64 to $3.92. HRMY shares are up 3.6% year to date.
Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters, while beating in just one, with the average negative surprise being 13.97%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 159.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said the company’s modified gene therapy platform is designed to address complex retinal diseases by modulating nuclear hormone receptors that regulate multiple gene networks, rather than targeting individual mutations. The company is advancing the platform in retinitis pigmentosa, Stargardt disease and geographic atrophy.
Musunuri said the three diseases represent a combined patient population of about 3 million people across the U.S. and Europe. Across its pipeline, including expanded-access-program patients, Ocugen has treated more than 325 patients across multiple doses and indications without observing a drug-related serious adverse event, he said.
Get Ocugen alerts:
The company said it remains on track to file three biologics license applications, or BLAs, by 2028. Ocugen expects top-line data for OCU400 and OCU410ST during the first half of 2027.
OCU410 Phase III Trial Planned for September Ocugen received FDA clearance to initiate its ArMaDa-3 Phase III registrational trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration. The company plans to begin the global trial by September 2026.
The study is expected to enroll about 237 participants and use a 2:1 randomization between the OCU410 treatment arm and control arm. Chief Medical Officer Mohammed Genead said participants will be followed for 12 months, with the study evaluating a primary efficacy endpoint as well as key functional endpoints.
Genead said the sample size and 95% statistical power were based on results from the prior ArMaDa-1 Phase I/II trial and were discussed with the FDA. The prior trial showed a statistically significant 31% reduction in geographic atrophy lesion growth at the selected dose among patients with lesion sizes between 2.5 and 17.5 square millimeters, according to Musunuri. The company also reported 27% preservation of the ellipsoid zone in that population.
Ocugen is targeting BLA and market authorization application filings for OCU410 in 2028. Musunuri said the company views geographic atrophy as its largest commercial opportunity, estimating a U.S. and European patient population of roughly 2 million to 3 million people.
Stargardt and Retinitis Pigmentosa Programs Advance For OCU410ST in Stargardt disease, Ocugen completed enrollment and dosing in the Phase II/III GUARDIAN3 pivotal confirmatory trial, which enrolled 63 participants. The company expects an interim outcome decision involving the first half of enrolled subjects during the third quarter of 2026 and top-line data in the second quarter of 2027. A BLA submission is planned for mid-2027.
Genead said the GUARDIAN3 study includes patients age 3 and older, a broad range of disease stages and lesion sizes, and variants associated with ABCA4-related retinopathy. The primary endpoint is lesion-based because the trial has a one-year duration, Musunuri said, while visual-function measures are being monitored as secondary endpoints.
In discussing earlier data, Genead said the company observed slowing of structural progression and functional benefits in its Phase I study. He said some patients demonstrated improvement in visual function, including a six-letter gain, or nearly one line, between treated and untreated eyes.
Meanwhile, enrollment has been completed in the Phase III liMeliGhT trial of OCU400 for retinitis pigmentosa. The trial enrolled 140 patients randomized 2:1 between treatment and control across RHO and gene-agnostic arms, encompassing more than 30 genetic mutations and patients from pediatric through later-stage disease populations.
Top-line data from liMeliGhT are expected in the first quarter of 2027. Ocugen said it could potentially receive approval for OCU400 in the fourth quarter of 2027, contingent on the expected regulatory process.
The primary endpoint in the trial is a 12-month change in visual function measured through luminance dependent navigation assessment. Musunuri said process performance qualification batches have been completed to support the BLA and commercial supply.
International and Commercial Planning In July, Ocugen signed a binding term sheet with Roots Pharmaceutical and strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400 in retinitis pigmentosa across the Middle East and North Africa.
Musunuri said the company has alignment from both the FDA and European Medicines Agency that the U.S. OCU400 trial could support approvals. He added that regulatory pathways in MENA and other regions are expected to be linked to U.S. FDA approval.
Ocugen said it is also pursuing other regional commercialization partnerships. Its commercial preparations include discussions with CMS and payers, identifying specialized treatment centers capable of subretinal procedures, assessing manufacturing and distribution needs, and building marketing and sales capabilities.
Quarterly Expenses Rise; Cash Runway Extended Into 2028 Chief Financial Officer Rita Johnson-Greene reported total operating expenses of $17.9 million in the second quarter, compared with $15.2 million in the prior-year quarter. Research and development expense rose to $10.7 million from $8.4 million, while general and administrative expense increased to $7.2 million from $6.8 million.
For the first six months of 2026, operating expenses totaled $37.3 million, compared with $31.2 million a year earlier. Ocugen reported a net loss of $0.07 per common share for the second quarter, compared with a loss of $0.05 per share in the year-earlier period.
Following a $130 million convertible notes financing, Ocugen had $100.4 million in cash equivalents and restricted cash as of June 30. Johnson-Greene said the financing extended the company’s cash runway into 2028 and supports execution of its late-stage clinical programs.
She also cited potential additional funding sources, including a priority review voucher tied to OCU410ST’s rare pediatric disease designation, potential regional business-development agreements, Janus Henderson warrants that could provide $15 million if exercised, and potential equity financing. Ocugen expects to hold a special meeting in September to seek an increase in authorized shares.
About Ocugen (NASDAQ:OCGN)Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.
In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Ocugen Right Now?Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDT
Company Participants
Chris Clark
Shankar Musunuri - Co-Founder, CEO & Chairman
Rita Johnson-Greene - CFO & Principal Accounting Officer
Mohamed Genead - Interim Chief Medical Officer
Conference Call Participants
Michael Okunewitch - Maxim Group LLC, Research Division
Whitney Ijem - Canaccord Genuity Corp., Research Division
Charles Wallace - H.C. Wainwright & Co, LLC, Research Division
Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division
Presentation
Operator
Good morning, and welcome to Ocugen's Second Quarter 2026 Financial Results and Business Update. [Operator Instructions]
I will now turn the call over to Chris Clark, Ocugen's Head of Communications. You may begin.
Chris Clark
Thank you, Operator, and good morning, everyone. Joining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's Chairman, CEO, and Co-Founder, who will provide a business update and an overview of our clinical and operational progress; Rita Johnson-Greene, our Chief Financial Officer, is also on the call to provide a financial update for the quarter ended June 30, 2026; Abhi Gupta, Executive Vice President of Commercial and Business Development; and Dr. Mohamed Genead, who joined Ocugen as Chief Medical Officer in June, will be available to answer questions following the presentation.
This morning we issued a press release covering our business and operational highlights for the second quarter of 2026. We encourage listeners to review the press release, which is available on our website at ocugen.com. A replay of this call, along with the accompanying slide presentation, will be available on the Investors section of the Ocugen website.
Please note that certain statements made during today's discussion may be forward-looking in nature, including those related to our clinical development pipeline, regulatory time lines, commercialization strategy, and financial information, and our anticipated cash runway. These statements reflect management's current expectations and are inherently subject
Ocugen (OCGN - Free Report) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -40.00%. A quarter ago, it was expected that this biotech knee implant developer would post a loss of $0.05 per share when it actually produced a loss of $0.06, delivering a surprise of -20%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
Ocugen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.49 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 6.29%. This compares to year-ago revenues of $1.37 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ocugen shares have lost about 5.2% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for Ocugen?While Ocugen has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ocugen was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.05 on $1.3 million in revenues for the coming quarter and -$0.22 on $4.14 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, CAMP4 Therapeutics Corporation (CAMP - Free Report) , is yet to report results for the quarter ended June 2026.
This company is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +61.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
CAMP4 Therapeutics Corporation's revenues are expected to be $1.35 million, down 10% from the year-ago quarter.
Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to initiate Phase 3 this quarter Granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA for OCU410, enabling eligibility for priority review and accelerated approval Signed a binding term sheet with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, to negotiate an exclusive license for OCU400 in retinitis pigmentosa (RP) across the Middle East and North Africa (MENA) region Successfully completed OCU400 Process Performance Qualification (PPQ) batches, supporting Biologics License Application (BLA) and commercial launch supplies Closed $130.0 million convertible senior notes financing, extending cash runway into 2028 Remain on track to announce top-line results for two late-stage clinical programs, OCU400 for RP and OCU410ST for Stargardt disease in 1Q 2027 and 2Q 2027, respectively Strengthened leadership team with the appointments of Mohamed Genead, M.D.
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor conferences in August 2026.
Oppenheimer 4th Annual Biotech in the Berkshires Summit
Location: Miraval Resort, Lenox, MA
Date: Tuesday, August 4, 2026
Time: 12:30–1:10 p.m. ET
Session Title: Beyond the Readout: Building Durable Value in Rare Diseases & Gen Meds
Format: Panel discussion
Panelists: Shankar Musunuri, Pratik Shah, Ram Aiyar, Frank Gleeson, Allan Reine
Moderators: Leland Gershell, Managing Director, Senior Analyst, Biotechnology, Oppenheimer & Co. Inc.; Kostas Biliouris, Managing Director, Senior Analyst, Biotechnology, Oppenheimer & Co. Inc.
Canaccord 46th Annual Growth Conference
Location: Intercontinental Hotel (Dartmouth/Eleanor Room), Boston, MA
Date: Tuesday, August 11, 2026
Time: 1:00–1:25 p.m. ET
Format: Fireside chat
Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen
A webcast of the Canaccord presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet needThe designation could accelerate OCU410’s regulatory path while further differentiating its one-time treatment for life approach from current therapies requiring chronic administration MALVERN, Pa, July 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to Ocugen’s investigational product OCU410 for the treatment of geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD).
"RMAT designation for OCU410 is a significant accomplishment that recognizes both the potential of our ‘one treatment for life’ novel gene therapy platform and the substantial unmet medical need for geographic atrophy,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. “With an estimated 2 to 3 million people in the U.S. and Europe affected, a number expected to grow as the population ages, geographic atrophy is a leading cause of irreversible blindness in older adults, highlighting the urgent need for new treatment options. We look forward to continuing to work closely with the FDA to responsibly and efficiently advance the development program for patients suffering from this devastating disease."
The RMAT designation for OCU410 was supported by Phase 2 clinical data demonstrating clinically meaningful efficacy and a favorable safety profile, with no reported serious adverse events related to drug. Based on these data, the FDA determined that OCU410 met the criteria for RMAT designation by providing preliminary clinical evidence that the therapy has the potential to address a serious condition with significant unmet medical need. This designation recognizes the promise of OCU410 as a regenerative medicine therapy and supports an expedited development pathway.
In early July 2026, Ocugen reached alignment with the FDA on the design of the OCU410 Phase 3 registrational trial, with study initiation expected in the third quarter of 2026, and a Biologics License Application (BLA) filing anticipated in 2028.
About Regenerative Medicine Advanced Therapy (RMAT) Designation
The FDA established the RMAT designation to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening diseases or conditions. RMAT designation is granted to investigational regenerative medicine therapies supported by preliminary clinical evidence indicating the potential to address unmet medical needs. Products receiving RMAT designation are eligible for all the benefits of the Fast Track and Breakthrough Therapy programs, including increased interactions with the FDA to support efficient development, eligibility for rolling BLA review, and the potential for accelerated approval and Priority Review, where appropriate.
About Dry Age-Related Macular Degeneration (dAMD) and Geographic Atrophy (GA)
Geographic atrophy is an advanced form of dAMD characterized by progressive degeneration of the macula, leading to irreversible central vision loss. Millions of patients worldwide are affected by GA, with a particularly high burden in aging populations in the United States and Europe. Despite recent approvals, treatment options remain limited and require chronic intravitreal injections, underscoring the need for innovative, durable therapies that address multiple disease mechanisms. dAMD affects approximately 10 million Americans and more than 266 million people worldwide. It is characterized by the thinning of the macula, the portion of the retina responsible for clear vision in one’s direct line of sight. dAMD involves the slow deterioration of the retina with submacular drusen (small white or yellow dots on the retina), atrophy, loss of macular function, and central vision impairment. dAMD accounts for 85-90% of all AMD cases.
About OCU410
OCU410 is an investigational, subretinal injection, AAV5-based gene therapy that delivers RORA (retinoid-related orphan receptor alpha), a nuclear receptor that regulates key pathways involved in retinal homeostasis, including oxidative stress response, complement regulation, inflammation, and lipid metabolism. OCU410 is being developed as a one-time gene therapy for patients with GA secondary to dAMD. OCU410 received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of enrollment and data readouts, the ability to initiate new clinical programs, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that receipt of RMAT designation may not lead to faster development or regulatory review; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our annual and quarterly filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 6, 2026.
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.
Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone payments totaling up to $4 million. The Company would be entitled to sales milestone payments up to $255 million, in addition to a 22% royalty on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen would manufacture commercial supply of OCU400 under the terms of a related supply agreement.
RP is a leading cause of inherited vision loss globally, with notable prevalence across the MENA region, underscoring the significant unmet need OCU400 is positioned to address through this partnership.
"This step forward represents an important milestone in our effort to advance OCU400 regional partnership strategy," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "By partnering with an established leader with strong reach across the Middle East and North Africa, we are expanding our ability to bring this one-time potential treatment for life to a region where RP is highly prevalent with a significant unmet medical need where patients are desperately looking for rescue from blindness. This agreement underscores the momentum behind OCU400 and our continued commitment to patients."
“Bringing innovative gene therapies to patients across the MENA region is a strategic imperative for Roots Pharmaceutical and its strategic partner Al-Dhow International Holding,” said Dr. Islam Zayed, CEO & Co founder of Roots Pharmaceutical. Dr.Zayed emphasized that “ OCU400 built on our legacy of bringing Rare Disease therapies to patients in MENA and enables our combined teams to decrease disease burden in the region. Importantly, Roots is dedicated to bringing OCU400 to patients with Retinitis Pigmentosa and creating a new treatment paradigm. We are excited to partner with the Ocugen team.”
Additional details will be available once the definitive agreement between the parties is executed, which is expected to occur within the next 90 days.
Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the terms of the definitive license and supply agreement with Roots Pharmaceutical, the timing of entering into such definitive agreement or whether such definitive agreement will be executed at all, the anticipated benefits to Ocugen of such definitive agreement, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that the definitive license and supply agreement with Roots Pharmaceutical will be delayed or not executed at all, or that, if executed, it will not be on terms described above, the risk that such definitive agreement, if executed, will not lead to the currently anticipated benefits to Ocugen, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigmentosa and Stargardt disease next year and a third BLA for geographic atrophy in 2028.
Speaking during a Piper Sandler discussion with analyst Biren Amin, Shankar said Ocugen is focused on inherited retinal diseases and dry age-related macular degeneration, including retinitis pigmentosa, Stargardt disease and geographic atrophy, the late form of dry AMD. He cited more than 100,000 retinitis pigmentosa patients in the U.S., about 50,000 Stargardt disease patients in the U.S. and 2 million to 3 million geographic atrophy patients in the U.S. and EU in the late stage of disease.
Get Ocugen alerts:
Shankar said Ocugen has retinitis pigmentosa and Stargardt programs in Phase 3 and expects to begin a global Phase 3 program for geographic atrophy in the third quarter, with alignment from regulators in the U.S. and Europe.
OCU410 Phase 3 Plans for Geographic Atrophy Amin began by asking about OCU410, Ocugen’s gene therapy candidate for geographic atrophy. Shankar said the therapy uses a modified RORA gene, which Ocugen is also using in its Stargardt program. He said RORA is intended to regulate multiple pathways involved in disease progression, including oxidative stress, lipid metabolism, inflammation and the complement system.
Shankar contrasted the approach with currently approved therapies that target the complement system, saying Ocugen believes RORA could help “reset” cellular homeostasis and create a healthier environment for photoreceptors and retinal pigment epithelial cells. He said Phase 2 data showed treatment benefit in one year, while many trials in the disease area run for at least two years.
Discussing Phase 2 results, Shankar said the medium dose showed about a 33% reduction in lesion growth when using the square root measure, while the company observed a bell-shaped dose-response pattern rather than a linear one. He said the high dose did not perform as consistently as the medium dose, leading Ocugen to select the medium dose for Phase 3.
For the pivotal study, Shankar said Ocugen plans to use a baseline lesion size range of 2.5 mm squared to 17.5 mm squared, consistent with approved products, and will measure the rate of change in lesion size at four-month intervals through 12 months. He said the company expects to enroll fewer than 300 patients and plans an adaptive design in which a data monitoring committee may review the trial after 50% of patients complete one year.
Shankar said Ocugen designed the trial assuming an effect size lower than the Phase 2 result, using roughly 25% to build in a buffer. Secondary endpoints will include ellipsoid zone preservation and low-luminance visual acuity. He said the medium dose showed about 27% preservation of ellipsoid zone loss in Phase 2, and the company hopes to see results in the 20%-plus range.
On safety, Shankar said there were no serious adverse events related to the drug in Phase 2, though some surgery-related issues can occur with vitrectomy and most resolved.
Stargardt Program OCU410ST Amin also asked about OCU410ST, Ocugen’s program for Stargardt disease. Shankar said Phase 1 results from the GARDian1 trial showed a 54% reduction in lesion growth in evaluable subjects compared with untreated eyes, using the contralateral eye as a control. He said the result informed the design of the Phase 2/3 pivotal study, which included 51 planned subjects, with 34 treated and 17 untreated.
Shankar said the company is also monitoring ellipsoid zone and low-luminance visual acuity as secondary measures. He said the program is intended as a one-time therapy and is being studied across a broad range of patients, including pediatric and adult patients aged three and older and patients from early to advanced stages of disease.
The GARDian3 pivotal trial includes an adaptive sample size re-estimation, which Shankar said is expected this quarter. He said the data monitoring committee could recommend no change, an adjustment in sample size or an extension of follow-up from 12 months to 16 months. Ocugen over-recruited the study to 63 patients, he said, potentially reducing the need for additional enrollment if the committee recommends a larger sample.
If no changes are made, Shankar said top-line results are expected in the second quarter of next year, followed by a BLA filing “a few weeks after that” or around mid-next year. If the timeline is extended, he said any delay could be roughly four to six months and still could allow the company to reach year-end next year. He also said no serious adverse events related to the drug have been observed so far in the Stargardt program.
OCU400 for Retinitis Pigmentosa Ocugen’s third program, OCU400, targets retinitis pigmentosa. Shankar said enrollment is complete in the Phase 3 trial, with top-line data expected in the first half of next year. He described the trial as a large genetic medicine study with 140 patients and more than 25 genetic mutations represented.
Shankar said OCU400 uses NR2E3 delivered through an AAV vector and is designed to be gene-agnostic by upregulating key transcription factors and helping reset cellular function. He said the trial includes a 2:1 randomization ratio, with more patients in the treatment arm than the control arm, and covers a broad population that includes syndromic and non-syndromic retinitis pigmentosa.
The primary functional assessment will use a Luminance Dependent Navigation Assessment, which Shankar said is similar to the multi-luminance mobility test used in the approval of Luxturna but modified to be more specific and sensitive. He said the trial will compare the rate of improvement over one year against the control arm.
Upcoming Milestones Shankar said Ocugen is aiming for two top-line readouts next year from its retinitis pigmentosa and Stargardt programs, followed by a third program readout in geographic atrophy in 2028. He reiterated the company’s goal of filing three BLAs over the next two years, followed by marketing authorization applications and potential global approvals.
“We’re going after with our one-time potential treatments, targeting hundreds of thousands to millions,” Shankar said, describing that as a key point of differentiation for the company.
About Ocugen NASDAQ: OCGNOcugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.
In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Ocugen Right Now?Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026.
Piper Sandler Virtual Ophthalmology Day – Fireside Chat
Date: Friday, July 10, 2026
Time: 10:00–10:25 a.m. EDT
Speaker: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen
Moderator: Biren Amin, Managing Director, Healthcare Equity Research, Piper Sandler & Co.
Location: DoubleTree Montreal
Date: Tuesday, July 14, 2026
1:45 p.m. EDT – Regenerative Approaches in Retinal Disease: From Genetic Repair to Functional Restoration
Panelists: Sally Tucker, Peter Francis, Shankar Musunuri, Dhaval Desai, Dina Akasheh, Thomas Ciulla
ASRS (American Society of Retina Specialists)
Location: Palais des Congrès de Montréal
Date: Friday, July 17, 2026
8:21–8:24 a.m. EDT – OCU410 Phase 2 ArMaDa 1-Year Results
Presenter: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research and Director of Fellowship, Sierra Eye Associates; Clinical Professor, University of Nevada, Reno School of Medicine
8:24–8:27 a.m. EDT – Phase 1/2 OCU410 Quantitative FAF/SD-OCT Analysis and Safety Outcomes
Presenter: Jay Chhablani, MD, Professor, University of Pittsburgh and UPMC Vision Institute; President, NetraMind
A webcast of the Piper Sandler presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Key Takeaways OCGN targets Q3 2026 rolling BLA for OCU400, with top-line Phase III data expected in Q1 2027.OCU410ST completed pivotal enrollment and dosing; interim data are due Q3 2026, top-line in Q2 2027.OCU410 plans a Phase III start in Q3 2026 after Phase II lesion-growth reduction signals and clean safety. Ocugen (OCGN - Free Report) is advancing three one-time gene therapy programs for retinal diseases, each aimed at conditions with large unmet needs and limited effective options.
The company’s late-stage calendar clusters multiple clinical readouts and regulatory steps into 2026 and 2027, setting up a dense catalyst window for a stock that can swing sharply on data and policy decisions.
OCGN’s 2026-27 Calendar in One ViewOcugen frames 2026 as pivotal because it expects meaningful milestones across all three core ocular programs in the same year. The cadence includes regulatory progress for the lead candidate and an interim clinical update for a second pivotal study, while a third program is positioned to enter Phase III.
That synchronization matters because it concentrates investor attention on a short list of binary events, rather than a long, diffuse development timeline. At the same time, the setup carries risk because the company has no approved products, burns cash, and remains dependent on high-risk trials and regulatory outcomes.
The first quarter of 2027 matters most for OCGN because it is the expected window for top-line Phase III results for the lead program. That readout sits directly on top of the company’s planned regulatory path and is the clearest single event in the stated 2026-27 timeline.
Ocugen’s Lead Programs and What They TreatOcugen’s three core retinal targets are retinitis pigmentosa, Stargardt disease, and geographic atrophy, each associated with progressive vision loss and limited treatment choices today. The company positions these programs around large underserved populations and a lack of effective options, particularly for Stargardt disease and geographic atrophy in Europe.
For retinitis pigmentosa, the company highlights broad genetic complexity, with mutations across more than 100 genes. It also points to the narrow reach of the only approved gene therapy approach cited, which targets a small fraction of the population.
For Stargardt disease, the emphasis is on the absence of approved options and a mutation profile that is wide enough to support a “one-time” approach that aims to address many disease-causing variants. For geographic atrophy, the company contrasts the burden of repeated injections in existing U.S. treatment with the goal of a one-time therapy that addresses multiple aspects of disease biology.
OCGN and OCU400: What Comes FirstOCU400 is Ocugen’s lead modifier gene therapy program for retinitis pigmentosa, and enrollment is complete in the Phase III liMeliGhT study, which enrolled 140 patients.
The next stated regulatory step is a rolling biologics license application targeted for the third quarter of 2026, positioning OCU400 toward a potential approval pathway in 2027 if the Phase III package supports it. The FDA has granted orphan drug designation for OCU400 in retinitis pigmentosa.
The company’s key clinical catalyst is top-line Phase III timing expected in the first quarter of 2027. Earlier studies are characterized as showing durable safety and meaningful vision improvement, which sets the baseline narrative going into the pivotal readout.
Ocugen and OCU410ST: Interim Data SetupOCU410ST is being developed as a one-time gene therapy for Stargardt disease, and enrollment and dosing have been completed in the Phase II/III GARDian3 pivotal confirmatory study.
The next milestones are staged: interim data are expected in the third quarter of 2026, followed by top-line results anticipated in the second quarter of 2027. That sequencing keeps Stargardt disease as a parallel catalyst stream alongside the OCU400 program.
Ocugen targets a mid-2027 biologics license application submission for OCU410ST. Earlier Phase I results are described as having the potential to provide clinically meaningful functional and structural benefits in Stargardt disease patients.
OCGN and OCU410: From Phase II Signal to Phase III StartOCU410 is being developed as a one-time gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The Phase II efficacy narrative emphasizes the medium dose as the optimal dose intended for Phase III development.
Across Phase II updates, Ocugen cites lesion-growth reduction signals versus control, including a 31% reduction at 12 months for the medium dose and a 54% reduction versus control for the medium dose in a separate disclosure of 12-month performance. The company also points to a clean safety profile with no treatment-related serious adverse events across studies cited.
The next development step is the plan to begin a Phase III registrational study in the third quarter of 2026, moving geographic atrophy into the same late-stage rhythm as the other programs.
Ocugen’s “Three Filings by 2028” GoalOcugen’s stated strategy is to run these programs on synchronized tracks, with three regulatory applications planned over the next three years, turning a multi-asset pipeline into a rolling series of potential catalysts.
This setup can create multiple moments for the market to reassess OCGN, especially as 2026 brings a rolling filing for OCU400, interim Stargardt data, and a planned Phase III start in geographic atrophy, followed by pivotal readouts in 2027.
The flip side is that the same tight calendar can amplify volatility. For context, other gene-therapy-focused names like REGENXBIO (RGNX - Free Report) and MeiraGTx Holdings (MGTX - Free Report) also operate in an event-driven clinical landscape, where trial updates and regulatory signals can reshape expectations quickly. For OCGN, the ultimate direction still depends on clinical execution and regulatory outcomes over 2026 and 2027.
OCGN’s Zacks RankOcugen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Key Takeaways OCGN targets multiple 2026 milestones, led by OCU400 rolling BLA plans and parallel pipeline readouts.Fiscal 2025 net loss was $67.8M as R&D and operating costs continued to outpace recurring revenue.Cash plus January financing funds operations into Q4 2026; warrants could extend runway to Q2 2027. Ocugen (OCGN - Free Report) is advancing a late-stage ophthalmology pipeline built around one-time gene therapies for retinal diseases with large unmet needs. Multiple clinical readouts and regulatory milestones expected in 2026 set up a catalyst-heavy calendar.
At the same time, the company remains a pre-commercial biotech with meaningful cash burn, making financing and dilution key variables investors need to track.
OCGN’s Investment Setup and What Can Go RightOcugen’s bull case centers on a synchronized late-stage pipeline in inherited retinal disease, with programs progressing on schedule and multiple planned regulatory steps over the next three years.
The lead asset, OCU400, is in a phase III study in retinitis pigmentosa, with enrollment complete and a rolling biologics license application targeted for the third quarter of 2026. Top-line data is expected in the first quarter of 2027, and the program has an orphan drug designation.
Two additional one-time gene therapies broaden the catalyst set. OCU410ST (Stargardt disease) has completed enrollment in its phase II/III pivotal confirmatory study, with interim data expected in the third quarter of 2026 and a biologics license application planned for mid-2027. OCU410 (geographic atrophy) is in phase II, with phase III expected to begin in the third quarter of 2026 following phase II updates.
Ocugen’s Biggest Bear Case: No Approved ProductsThe core bear case is simple: Ocugen has no approved products and limited commercial revenue to fund operations. That leaves the stock highly sensitive to clinical execution and regulatory outcomes.
Revenue has been inconsistent, reflecting collaboration-related recognition rather than product sales. Fiscal 2025 revenue was $4.4 million, and fourth-quarter fiscal 2025 revenue was negative $0.2 million.
Any meaningful delay in pivotal timelines, manufacturing readiness, or regulatory feedback can quickly change the valuation narrative because the investment case relies on late-stage progress converting into filings and, ultimately, approvals.
OCGN’s Cash Burn and Loss Profile in Plain EnglishOcugen’s financial profile reflects an R&D-intensive company preparing multiple assets for late-stage studies and pre-commercial activity. In fiscal 2025, research and development expense rose to $39.8 million and general and administrative expense totaled $27.6 million.
Those costs drove a fiscal 2025 net loss of $67.8 million. Put plainly, spending is running far ahead of recurring revenue, so external funding remains a central part of the story as programs advance.
The fourth quarter showed the same dynamic, with total operating expenses of $17.0 million and a net loss of $17.7 million, underscoring that losses can widen when program activity and readiness work accelerate.
Ocugen’s Runway Through Late 2026 and What Extends ItLiquidity is improving, but it is still time-limited. Year-end cash was $18.9 million, and Ocugen raised $22.5 million in gross proceeds in January 2026. Together, management expects these resources to fund operations into the fourth quarter of 2026.
There is a potential runway extender: full exercise of $30 million of outstanding warrants could extend funding into the second quarter of 2027. That scenario depends on warrant exercise, so it should be treated as conditional support rather than guaranteed capital.
Even with that extension, the timeline still looks tight versus the company’s own expectations that its first commercial approval is not expected before 2027. That mismatch is why financing risk remains part of the base case.
OCGN’s Dilution Risk and How To Watch ItBecause the runway only reaches late 2026 on current funding plans, the most practical way to monitor dilution risk is to track whether spending and milestone timing stay aligned. The company has flagged that it will likely require additional capital to support multiple pipeline and commercial priorities.
Key watch-items include: (1) the operating expense trajectory as phase III activities and manufacturing work scale, (2) timing of pivotal and interim readouts that can influence financing terms, and (3) costs tied to regulatory filing preparation as biologics license application work ramps.
Investors can also watch for additional regional monetization. The strategy of licensing select geographies, like the Korea rights deal for OCU400, is positioned as a way to strengthen liquidity while retaining broader upside.
Ocugen’s Neutral View and a Practical Decision FrameThe current framing is a Neutral view that reflects meaningful upside optionality from catalysts, balanced by the realities of pre-commercial risk and funding needs.
A practical checklist to raise conviction starts with execution: clean, on-schedule clinical updates in 2026, continued progress toward the targeted OCU400 rolling biologics license application in the third quarter of 2026, and credible advancement of OCU410ST and OCU410 toward their next inflection points.
The risk checklist is equally clear: any pipeline or regulatory setback, a faster-than-expected spending ramp, or financing actions that materially expand the share count ahead of value-creating data.
For context, early-to-mid-stage biotech investors often compare Ocugen’s setup with other gene therapy-focused developers such as REGENXBIO (RGNX - Free Report) and Sarepta Therapeutics (SRPT - Free Report) , both of which highlight how quickly sentiment can shift when trial updates, safety signals, and funding decisions hit the tape.
OCGN’s Zacks RankOcugen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways OCGN says OCU400 could address 98% to 99% of retinitis pigmentosa patients across mutations.OCU410ST targets Stargardt disease with interim data due Q3 2026 and top-line results in Q2 2027.OCU410 plans Phase III in Q3 2026 after Phase II lesion-growth reduction signals in geographic atrophy. Ocugen (OCGN - Free Report) is pushing a modifier gene therapy platform across several retinal diseases where current options are limited, burdensome, or simply absent. The common thread is a “gene-agnostic” concept that aims to help broad patient groups with one-time treatment rather than chasing single mutations one by one.
With multiple late-stage timelines converging and several 2026 readouts and regulatory steps on the calendar, the setup is increasingly catalyst-driven. At the same time, Ocugen has no approved products and continues to burn cash, keeping risk elevated.
OCGN’s Modifier Gene Therapy Explained SimplyInherited retinal diseases like retinitis pigmentosa can be caused by many different genetic mutations. Ocugen’s modifier gene therapy platform is designed to work across mutations, rather than matching a therapy to a single defective gene.
That stands apart from a mutation-specific paradigm, where treatment eligibility can narrow sharply depending on the patient’s exact gene defect. In practice, Ocugen is trying to make one therapy relevant to many genetic subtypes, which could expand both clinical utility and commercial reach if efficacy and safety hold up in late-stage testing.
Ocugen’s “Broad Coverage” Claim in RPRetinitis pigmentosa is associated with mutations in more than 100 genes, creating a fragmented landscape for drug development. The company’s framing highlights that there is only one approved gene therapy for retinitis pigmentosa, and it targets a single mutation representing about 1% to 2% of the total retinitis pigmentosa population.
OCU400 is positioned as a one-time subretinal injection that could treat multiple gene mutations, with the potential to cover about 98% to 99% of all retinitis pigmentosa patients. Enrollment is complete in the Phase III liMeliGhT study, and top-line data is expected in the first quarter of 2027. The company expects to begin filing a rolling biologics license application in the third quarter of 2026, supported by ongoing Chemistry Manufacturing and Controls work. The Food and Drug Administration has also granted orphan drug designation to OCU400 for retinitis pigmentosa.
OCGN’s One-Time Approach in Stargardt DiseaseOCU410ST is being developed as a one-time gene therapy for Stargardt disease, a condition with no Food and Drug Administration-approved treatments. That lack of approved options is a key reason the upcoming clinical updates carry high attention potential.
Ocugen’s patient population framing emphasizes scale and genetic complexity. Stargardt disease affects roughly 100,000 patients in the United States and the European Union and about 1 million globally. OCU410ST is positioned to address more than 1,200 disease-causing mutations in the ABCA4 gene with a single therapy, including ABCA4-related retinopathies. Enrollment and dosing have been completed in the Phase II/III GARDian3 pivotal confirmatory study, with interim data expected in the third quarter of 2026 and top-line data anticipated in the second quarter of 2027. A biologics license application submission is targeted for mid-2027.
Ocugen’s GA Thesis Beyond Anti-ComplementGeographic atrophy is another area where Ocugen is arguing for a shift in the treatment paradigm. The company notes that current options can require multiple injections and focus on one aspect of disease, while OCU410 is intended as a one-time gene therapy that addresses multiple aspects beyond the complement pathway.
In Phase II, preliminary signals highlighted lesion growth reduction at 12 months. The company has described a 46% lesion growth reduction across the medium- and high-dose groups versus control, with the medium dose showing the strongest effect. A later 12-month update described a 31% reduction versus control at the medium dose and reiterated that the medium dose is intended for Phase III development. Phase III is planned to begin in the third quarter of 2026.
This is also where comparisons naturally arise to companies building around complement inhibition. Apellis Pharmaceuticals , for example, remains a closely watched name in geographic atrophy, and it currently carries a Zacks Rank #3 (Hold).
OCGN’s De-Risking Attempts Through PartnershipsWith no marketed products, Ocugen’s strategy includes monetizing select geographies while keeping broader upside. In 2025, the company signed its first licensing agreement with Kwangdong Pharmaceutical for exclusive South Korea rights to OCU400, explicitly framed as regional monetization without giving up global opportunity.
Collaborative revenue is expected to come from licensing, milestones, royalties, and supply. Fiscal 2025 revenue totaled $4.4 million, driven primarily by the CanSinoBIO co-development and commercialization agreement, while no revenue was recognized under the Kwangdong OCU400 agreement in 2025 because there was no product delivery during the period.
Ocugen’s Platform Optionality Beyond OphthalmologyBeyond the lead ocular gene therapy programs, Ocugen has several programs that can diversify risk but remain early or execution-dependent. OCU200 is a novel biologic in Phase I for retinal vascular diseases, and the company has navigated prior regulatory delays that pushed timelines out before the program moved forward.
NeoCart is described as a Phase III-ready regenerative cell therapy for knee cartilage repair, adding a non-ophthalmology asset with nearer-term development readiness. The inhaled mucosal vaccine platform, including OCU500, OCU510 and OCU520, broadens exposure to infectious diseases and has external support, including National Institute of Allergy and Infectious Diseases backing for planned Phase I initiation.
Investors weighing platform optionality often benchmark against other gene-therapy-focused developers. Sarepta Therapeutics (SRPT - Free Report) , a prominent name in genetic medicine, currently carries a Zacks Rank #3 (Hold).
OCGN's Zacks RankOcugen currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy.
“I look forward to sharing our story with new audiences and building enthusiasm for why now is the time to get to know Ocugen,” said Dr. Musunuri. “Our gene-agnostic approach to addressing all mutations related to major blindness diseases has the potential to be first-in-class—disrupting existing treatment paradigms and bringing gene therapy to the masses. With our planned BLA submission for OCU400 beginning later this year, commercialization is within reach.”
Innovation on the Island will include panels, company presentations, and networking opportunities. Biotech investors based in Puerto Rico as well as the continental United States will be in attendance.
The Cell & Gene Meeting on the Med brings together the ATMP community from Europe and beyond and covers a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing. Ocugen is a proud member and collaborator with the meeting’s organizer, the Alliance for Regenerative Medicine.
Details on the Company presentations are as follows:
Innovation on the Island
Date: Tuesday, April 28, 2026
Time: 8:20 a.m. AST
Location: Four Seasons Bahia Beach Resort
Meeting on the Med
Date: Tuesday, April 28, 2026
Time: 4:30 p.m. CEST
Location: Rome Cavalieri, Salone dei Cavalieri, Section 1
Executive Leadership looks forward to providing updates on Ocugen’s novel modifier gene therapy platform, including near-term key catalysts, during one-on-one opportunities at these important conferences.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications [email protected]
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026.
MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market conditions and other factors, $115 million aggregate principal amount of Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ocugen also expects to grant the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Ocugen intends to use approximately $32.7 million of the net proceeds from the offering to fully repay the outstanding principal amount of, plus accrued and unpaid interest on, the loan outstanding under its Loan and Security Agreement with affiliates of Avenue Capital Group and pay the related prepayment fee and other fees and expenses in connection therewith. Ocugen expects to use the remaining net proceeds from the offering, including any additional proceeds from the initial purchaser’s exercise of its option to purchase additional notes, for general corporate purposes.
The notes will be Ocugen’s general unsecured obligations and will rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to all of its existing and future liabilities that are not so subordinated, and junior to all of its secured indebtedness, to the extent of the value of the assets securing such indebtedness. Interest will be payable semi-annually in arrears. The notes may be converted into cash, shares of Ocugen’s common stock or a combination thereof, at Ocugen’s election. The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering.
The notes will only be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the notes nor the shares of Ocugen’s common stock potentially issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from such registration requirements.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including but not limited to, statements regarding the proposed terms of the notes; the anticipated terms of the notes; the size of the offering, including the initial purchaser’s option to purchase additional notes; the anticipated use of proceeds from the offering, including the repayment of the existing loan facility; the completion of the offering, and other statements contained in this press release that are not historical facts. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to: uncertainties related to market conditions and whether the offering will be completed on the anticipated terms or at all; the impact of the offering on the market price of Ocugen’s common stock; risks related to the potential dilution to holders of Ocugen’s common stock; and uncertainties regarding the conversion price and other terms of the notes. These and other risks and uncertainties are more fully described in Ocugen’s periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ocugen also granted the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The sale of the notes to the initial purchaser is expected to close on May 7, 2026, subject to customary closing conditions, and is expected to result in approximately $99.5 million (or approximately $112.6 million if the initial purchaser exercises its option to purchase additional notes in full) in net proceeds to Ocugen after deducting the initial purchaser’s discount and estimated offering expenses payable by Ocugen.
The offering price of the notes is 90% of the principal amount of notes. Ocugen intends to use approximately $32.7 million of the net proceeds from the offering to fully repay the outstanding principal amount of, plus accrued and unpaid interest on, the loan outstanding under its Loan and Security Agreement with affiliates of Avenue Capital Group (the “Avenue Loan Agreement”), and pay the related prepayment fee and other fees and expenses in connection therewith. Ocugen expects to use the remaining net proceeds from the offering, including any additional proceeds from the initial purchaser’s exercise of its option to purchase additional notes, for general corporate purposes.
The notes will be Ocugen’s general unsecured obligations and will rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to all of its existing and future liabilities that are not so subordinated, and junior to all of its secured indebtedness, to the extent of the value of the assets securing such indebtedness. Interest will be payable semi-annually in arrears. The notes will bear interest at a rate of 6.75% per year. Interest will be payable semi-annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2026. The notes will mature on May 15, 2034, unless earlier repurchased, redeemed or converted.
Ocugen may not redeem the notes prior to May 15, 2029. Ocugen may redeem for cash all or any portion of the notes (subject to certain limitations), at its option, on or after May 15, 2029 and prior to the 41st scheduled trading day immediately preceding the maturity date, if the last reported sale price of Ocugen’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Ocugen provides notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Holders of the notes may require Ocugen to repurchase for cash all or any portion of their notes on May 15, 2032 at a repurchase price equal to 100% of the principal amount of notes to be repurchased, plus accrued and unpaid interest to, but excluding May 15, 2032. In addition, holders of the notes will have the right to require Ocugen to repurchase all or a portion of their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price of 100% of their principal amount plus any accrued and unpaid interest to, but excluding, the relevant fundamental change repurchase date.
The notes may not be converted prior to the earlier of (i) May 15, 2027 and (ii) the “reserved share effective date” (as defined in the indenture governing the notes), which is effectively the date on which Ocugen reserves the maximum number of shares of common stock underlying the notes. The notes will be convertible at an initial conversion rate of 372.7866 shares of Ocugen’s common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $2.68 per share, which represents a conversion premium of approximately 45% to the last reported sale price of $1.85 per share of Ocugen’s common stock on The Nasdaq Capital Market on May 4, 2026). Conversions of the notes may be settled in cash, shares of Ocugen’s common stock, or a combination thereof, at Ocugen’s election; provided that unless and until the reserved share effective date occurs, conversions of the notes will be settled via cash settlement.
The notes were only offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the notes nor the shares of Ocugen’s common stock potentially issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from such registration requirements.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including but not limited to, statements regarding the anticipated use of proceeds from the offering, including the repayment of the Avenue Loan Agreement; the completion of the offering, and other statements contained in this press release that are not historical facts. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to: risks related to the offering and uncertainties related to market conditions; the impact of the offering on the market price of Ocugen’s common stock; and risks related to the potential dilution to holders of Ocugen’s common stock. These and other risks and uncertainties are more fully described in Ocugen’s periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p 30% reduction in Iesion growth compared to control, with a favorable safety and tolerability profile Allows robust registrational Phase 3 trial design, a potential combined U.S./EU trial with 300 subjects, with adaptive design powered at over 95% Trial enrollment complete for OCU400 for retinitis pigmentosa (RP) and OCU410ST for Stargardt disease registration trials, and on target to complete two Biologics License Application (BLA) submissions by 2027 The closing of a private offering of $115 million aggregate principal amount ($130 million if overallotment is exercised) of 6.75% convertible senior notes due 2034, with a conversion premium of 45%, is expected to extend cash runway into 2028, subject to customary closing conditions The Company expects to utilize $32.7 million of net proceeds from the Notes to retire the Avenue debt (12.5% interest rate) MALVERN, Pa.
Ocugen (OCGN - Free Report) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -12.57%. A quarter ago, it was expected that this biotech knee implant developer would post a loss of $0.06 per share when it actually produced a loss of $0.06, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Ocugen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.53 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 27.75%. This compares to year-ago revenues of $1.48 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ocugen shares have added about 37% since the beginning of the year versus the S&P 500's gain of 5.2%.
What's Next for Ocugen?While Ocugen has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ocugen was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.05 on $1.2 million in revenues for the coming quarter and -$0.22 on $5.4 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Sutro Biopharma, Inc. (STRO - Free Report) , has yet to report results for the quarter ended March 2026.
This company is expected to post quarterly loss of $2.32 per share in its upcoming report, which represents a year-over-year change of +74.5%. The consensus EPS estimate for the quarter has been revised 14.9% higher over the last 30 days to the current level.
Sutro Biopharma, Inc.'s revenues are expected to be $8.96 million, down 48.5% from the year-ago quarter.
Key Takeaways OCGN posted a Q1 loss of 6 cents per share, wider than estimates and the prior-year loss.Ocugen's expenses rose on accelerated R&D and commercial preparation, lifting operating costs.OCGN advanced gene therapy pipeline, reporting strong OCU410 data and achieving key trial milestones. Ocugen (OCGN - Free Report) incurred a loss of 6 cents per share in the first quarter of 2026, wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents.
Ocugen’s total revenues rose 3.5% year over year to $1.5 million in the first quarter, beating the Zacks Consensus Estimate of $1 million.
The company’s top line currently comprises only collaboration revenues.
OCGN’s Q1 Results in DetailOcugen’s operating expenses increased during the quarter as the company accelerated clinical development and commercial preparation activities.
Research and development expenses were $11.3 million, up 18.1% from the year-ago quarter’s level. General and administrative expenses totaled $8.1 million, up 25.8% year over year.
As of March 31, 2026, Ocugen had cash, cash equivalents and restricted cash worth $32.2 million compared with $18.9 million as of Dec. 31, 2025. Management stated that the company expects its recent $115 million convertible senior notes offering to extend the cash runway into 2028.
OCGN’s Pipeline Progress & Clinical UpdatesOcugen continued to make significant progress across its ophthalmology gene therapy portfolio during the quarter, with management targeting three biologics license application (BLA) submissions by 2028.
In March, the company completed patient enrollment in the phase III liMeliGhT registrational study on OCU400 for the treatment of patients with retinitis pigmentosa, a rare genetic disorder that can lead to vision loss and blindness. Top-line data is expected in the first quarter of 2027. OCGN plans to begin a rolling BLA submission in the third quarter of 2026 and complete it by the second quarter of 2027. Potential FDA approval is anticipated in the fourth quarter of 2027.
Ocugen also achieved an important milestone for another gene therapy candidate, OCU410ST. In April, the company completed enrollment and dosing in the phase II/III GARDian3 pivotal confirmatory study evaluating OCU410ST for the treatment of Stargardt disease, a rare inherited retinal disorder with no approved treatments currently available. The milestone was achieved ahead of schedule.
Top-line data is anticipated in the second quarter of 2027. The company targets a mid-2027 BLA submission for OCU410ST.
One of the quarter’s most important developments was positive 12-month top-line data from the phase II ArMaDa study evaluating OCU410 in geographic atrophy secondary to dry age-related macular degeneration.
The therapy achieved a statistically significant 31% reduction in lesion growth at the optimal (medium) dose compared with the control group and showed approximately 27% slower rate of ellipsoid zone loss, a key indicator linked to visual function. Around 20% of treated patients experienced no disease progression, while nearly 75% achieved more than a 30% reduction in lesion growth.
Based on the data, OCGN plans to initiate a phase III registrational study in the third quarter of 2026 with potential BLA filing by 2028.
Shares of OCGN fell sharply by around 19% on Tuesday despite key timelines for its pipeline candidates being maintained. The decline could be because investors focused more on the company’s rising costs and operating losses along with the earnings release. Ocugen recently announced and priced a $115 million private offering of 6.75% convertible senior notes due 2034, with an option to raise an additional $15 million. This may have weighed on investor sentiment as the potential increase to $130 million raised concerns about dilution and higher future debt obligation.
Year to date, shares of OCGN have risen 10.4% against the industry’s 2.4% decline.
Image Source: Zacks Investment Research
OCGN's Zacks Rank & Stocks to ConsiderOcugen currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Castle Biosciences (CSTL - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy) and Catalyst Pharmaceuticals (CPRX - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.42 to $1.40. Over the same period, loss per share estimates for 2027 have also narrowed from 79 cents to 78 cents. CSTL shares have lost 36.7% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.26. Over the same period, EPS estimates for 2027 have risen from $3.40 to $3.57. INDV shares have risen 10.3% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have declined from $2.82 to $2.79. Over the same period, EPS estimates for 2027 have surged from $3.20 to $3.28. CPRX shares have gained 32.3% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Ocugen (OCGN - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for Ocugen basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Ocugen imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for OcugenFor the fiscal year ending December 2026, this biotech knee implant developer is expected to earn -$0.20 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Ocugen. Over the past three months, the Zacks Consensus Estimate for the company has increased 23.1%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Ocugen to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026.
Retina World Congress
Inherited and Rare Retinal Diseases Session
Moderators: Kourous A. Rezaei, MD and Rishi P. Singh, MD, FASRS
Location: Grand Ballroom
Date: Thursday, May 14, 2026
Time: 10:31 am – 11:10 a.m. EDT
Stifel 2026 Virtual Ophthalmology Forum
Location: Virtual
Date: Tuesday, May 26, 2026
Time: 10:30 am – 10:55 a.m. EDT
A webcast of the Stifel presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Includes Full Exercise of $15.0 million Over-Allotment Option May 14, 2026 16:30 ET | Source: Ocugen
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), including the full exercise by the initial purchaser of its option to purchase an additional $15.0 million aggregate principal amount of the notes. The sale of the notes is expected to result in approximately $112.6 million in net proceeds to Ocugen after deducting the initial purchaser’s discount and estimated offering expenses payable by Ocugen.
The offering price of the notes was 90% of the principal amount of the notes. Ocugen used approximately $32.7 million of the net proceeds from the offering to fully repay the outstanding principal amount of, plus accrued and unpaid interest on, the loan outstanding under its Loan and Security Agreement with affiliates of Avenue Capital Group (the “Avenue Loan Agreement”), and pay the related prepayment fee and other fees and expenses in connection therewith. Ocugen expects to use the remaining net proceeds from the offering for general corporate purposes.
"This financing milestone reflects the strong momentum we have built across our late-stage pipeline and our unwavering commitment to the patients we serve," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen. "With our anticipated cash runway extended into 2028, we are well-positioned to advance three late-stage programs and execute toward our goal of filing three BLAs by 2028, bringing potentially transformative therapies to patients who have long awaited meaningful treatment options."
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including but not limited to, statements regarding the anticipated use of proceeds from the offering, Ocugen’s anticipated cash runway, the timing of future BLA filings, the potential to bring therapies to patients, and other statements contained in this press release that are not historical facts. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to: risks related to the offering and uncertainties related to market conditions; the impact of the offering on the market price of Ocugen’s common stock; and risks related to the potential dilution to holders of Ocugen’s common stock. These and other risks and uncertainties are more fully described in Ocugen’s periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026.
Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference
Date: Thursday, June 4, 2026
Time: 2:30pm EDT
Clinical Trials at the Summit 2026
Location: Fontainebleau Las Vegas
Date: Saturday, June 13, 2026
Time: 10:19 – 10:39 am PDT
Inherited Retinal Diseases: Transforming the Future Through Innovation
Moderator: Peter Kaiser
Panelists: Lance Baldo, Paul Bresge, Eliot Lazar, George Magrath, Nathan Mata, Shankar Musunuri, Jayashree Sahni
BIO International Convention
Location: Theater 3
Date: Tuesday, June 23, 2026
Time: 11:00 am PDT
A webcast of the Noble presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Key Takeaways OCGN is advancing OCU400, OCU410ST and OCU410, with key data readouts expected in 2027.OCGN completed phase III OCU400 enrollment; top-line data is expected in Q1 2027.OCGN targets an OCU410ST BLA in mid-2027 and a potential OCU410 filing by 2028. Ocugen (OCGN - Free Report) is advancing one-time subretinal gene therapies for inherited retinal diseases where patients face large unmet need and limited treatment options. With three lead ocular programs moving through mid- and late-stage development on overlapping schedules, the company is setting up a catalyst calendar that runs into 2028.
OCGN’s Three Core Programs and Why They MatterOcugen’s three lead ocular programs are OCU400 for retinitis pigmentosa in phase III, OCU410ST for Stargardt disease in phase II/III and OCU410 for geographic atrophy secondary to dry age-related macular degeneration in phase II. The platform is built around one-time subretinal dosing intended to reach broad patient populations within each disease.
Management has described its timelines as synchronized, which raises the odds of multiple meaningful updates landing within the same 12 to 18 months.
Ocugen Targets RP, Stargardt, and GA With One-Time DosingOcugen is targeting RP, Stargardt, and GA because current options are limited or ineffective for many patients. The company also highlights differentiated mechanisms of action in its retinal gene therapy work, supporting a strategy aimed at broad patient reach.
OCGN Timeline From 2026 Updates to 2027 Data ReadoutsOCU410 has already delivered phase II ArMaDa findings. Twelve-month top-line data showed a statistically significant 31% reduction in lesion growth versus control at the intended medium dose, along with 27% ellipsoid zone preservation. Ocugen plans to begin a phase III registrational study in the third quarter of 2026.
For OCU400, enrollment is complete in the phase III liMeliGhT study (140 patients), and top-line data is expected in the first quarter of 2027. For OCU410ST, the company completed enrollment and dosing in April 2026, with top-line data expected in the second quarter of 2027.
Ocugen’s Plan for Three BLAs and What Could SlipOcugen has stated a goal of submitting three biologics license applications by 2028. The planned timing includes an OCU410ST biologics license application in mid-2027, a potential OCU410 filing by 2028, and an OCU400 filing path tied to the first-quarter 2027 phase III data and a potential 2027 approval timeline.
Clinical timelines and regulatory review can move, and Ocugen has cited past regulatory delays as a risk factor for investors to monitor.
OCGN Revenue Base and Cash Runway After 2026 FinancingOcugen’s current revenue base is collaboration-driven. Total revenues rose 3.5% year over year to $1.5 million in the first quarter of 2026, and the company notes that its top line currently comprises only collaboration revenues.
Cash, cash equivalents and restricted cash were $32.2 million at March 31, 2026, after $37.5 million of gross proceeds raised in the first quarter. In May 2026, Ocugen completed a $130 million convertible notes offering with expected net proceeds of about $112.6 million, repaid its Avenue Capital loan, and management stated the financing extends the company’s cash runway into 2028.
Ocugen Risks That Can Change the Catalyst NarrativeOcugen has no approved products and continues to burn cash, making execution on high-risk trials and regulatory approvals the main driver of volatility. First-quarter 2026 operating cash use was $21.8 million, and the company disclosed that March 31, 2026 cash was not sufficient to fund the next 12 months without additional funding, before the convertible notes closed.
The convertible structure adds leverage and potential share dilution if converted, which can amplify downside if clinical or regulatory progress slips.
Adverum Biotechnologies, which was recently acquired by Eli Lilly (LLY - Free Report) and REGENXBIO (RGNX - Free Report) , also underscores the industry push toward ocular gene therapy and one-time treatment concepts.
OCGN’s Zacks RankOcugen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways OCGN expects key OCU400 and OCU410ST data in 2027, with filings targeted through 2028.OCGN raised capital and says its May 2026 financing extends cash runway into 2028.OCGN has no approved products and faces dilution, cash burn, and regulatory execution risks. Ocugen (OCGN - Free Report) is pushing three eye gene therapy programs toward late-stage regulatory timelines, setting up a catalyst-heavy stretch in 2026 and 2027. That opportunity comes with familiar biotech trade-offs. The company has no approved products, spends heavily to move trials forward, and has leaned on capital markets to extend its runway. The key question is whether upcoming clinical milestones justify the dilution and execution risk.
OCGN Q1 2026 Loss, Sales, and Expense TrendsOcugen posted a first-quarter 2026 loss of 6 cents per share, wider than both the year-ago loss of 5 cents per share and the Zacks Consensus Estimate.
Revenue was a bright spot. Total revenue rose 3.5% year over year to $1.5 million, beating the Zacks Consensus Estimate of $1.0 million, with the current top line driven by collaboration revenue.
Operating costs moved higher as the company accelerated clinical development and commercial preparation. Research and development expense was $11.3 million, up 18.1% year over year, while general and administrative expense totaled $8.1 million, up 25.8%.
Ocugen’s Cash Position and Why Dilution Still MattersCash burn remains a central risk variable. First-quarter 2026 operating cash use was $21.8 million, underscoring the pressure to keep funding the pipeline while trials and filings ramp.
Ocugen bolstered liquidity through multiple actions. In the first quarter, it raised $37.5 million in gross proceeds, including $22.5 million from a registered direct offering and $15.0 million from warrant exercises. Cash, cash equivalents, and restricted cash increased to $32.2 million as of March 31, 2026, up from $18.9 million at the end of 2025.
The bigger step came in May 2026, when Ocugen completed a convertible senior notes financing that raised $130 million after the full exercise of an overallotment option, with net proceeds of about $112.6 million. The company used a portion of the proceeds to fully repay its Avenue Capital loan and related obligations, and management said the financing extends the cash runway into 2028.
OCGN Gene Therapy Upside Into 2027 and BeyondOcugen’s upside case is built around a synchronized sequence of late-stage milestones across three ocular programs. Enrollment is complete in the phase III liMeliGhT study for OCU400 in retinitis pigmentosa, with top-line data expected in the first quarter of 2027.
On the Stargardt disease program, OCU410ST has completed enrollment and dosing in the phase II/III GARDian3 pivotal confirmatory study. Ocugen expects interim data in the third quarter of 2026 and top-line data in the second quarter of 2027, with a biologics license application filing planned for mid-2027.
For geographic atrophy, Ocugen plans to initiate a registrational phase III study of OCU410 in the third quarter of 2026. That keeps the company aligned with its goal of filing three biologics license applications by 2028.
Ocugen’s GA Data Versus Current Options in Dry AMDIn geographic atrophy secondary to dry age-related macular degeneration, Ocugen’s phase II ArMaDa readout supports its dose strategy heading into the planned registrational study. At 12 months, the intended medium dose produced a statistically significant 31% reduction in lesion growth versus control, along with 27% ellipsoid zone preservation.
Earlier 12-month data also pointed to a stronger signal: a 46% lesion growth reduction across the medium- and high-dose groups, and a 54% lesion reduction for the medium dose versus control.
Dose selection matters because the phase III design will likely lean on the dose that best balances efficacy and consistency. Ocugen has identified the medium dose as the optimal dose intended for phase III development, which is a key execution point as the program moves from signal generation to a registrational setting.
For context, today’s approved geographic atrophy therapies include Syfovre from Apellis Pharmaceuticals, which was recently acquired by Biogen (BIIB - Free Report) and Izervay from Astellas Pharma (ALPMY - Free Report) , both approved in 2023, and both delivered via repeated intravitreal injections.
OCGN Valuation Multiples and What Investors Are Pricing InOcugen trades at a premium sales multiple that reflects high optionality. The shares are valued at 46.05X forward 12-month sales per share, versus 1.96X for the Zacks sub-industry, 2.13X for the Zacks sector, and 5.27X for the S&P 500.
That premium also needs to be framed against volatility. Over the past five years, the stock has traded as high as 501.84X and as low as 2.08X, with a five-year median of 73.70X.
Performance metrics reinforce the same message. The shares were down 0.7% year to date but up 51% over the past year, signaling that investors are already discounting the possibility of meaningful inflection points around 2027 and 2028 milestones.
Ocugen Decision Checklist for Risk-Tolerant InvestorsThe clearest “green lights” are operational. Ocugen has late-stage alignment across OCU400, OCU410ST, and OCU410, with planned phase III execution and filings that support the stated goal of three biologics license applications by 2028, alongside management’s stated runway extension into 2028.
The “red flags” are equally direct. The company has no approved products, revenue is currently collaboration-driven, cash burn is heavy, and the capital structure now includes convertible notes that can create dilution risk if converted, alongside added leverage. Past regulatory delays, such as the earlier clinical hold on OCU200, also show how timelines can slip.
A milestone-based approach fits this setup. In 2026, investors can watch for the planned phase III start for OCU410 in the third quarter, the OCU400 rolling biologics license application timing in the third quarter, and interim data for OCU410ST in the third quarter. In 2027, the most important swing factors are top-line data from OCU400 in the first quarter and OCU410ST in the second quarter.
OCGN’s Zacks RankOcugen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways OCGN's OCU400 targets multiple RP mutations with phase III top-line data due in Q1 2027.OCGN plans a mid-2027 BLA for OCU410ST after phase II/III Stargardt data in Q2 2027.OCGN aims to start phase III for OCU410 in Q3 2026 after positive phase II GA findings. Ocugen (OCGN - Free Report) is advancing a retinal pipeline built around durability and breadth. Its focus is a modifier gene therapy platform aimed at inherited retinal diseases and blindness conditions, using one-time subretinal dosing intended to reach broad patient populations within each disease.
With retinitis pigmentosa, Stargardt disease and geographic atrophy programs moving toward late-stage milestones, 2026 and 2027 set up as defining years for clinical execution and regulatory progress.
OCGN’s Modifier Gene Therapy Platform, ExplainedOcugen’s strategy is to use modifier gene therapy to address inherited retinal diseases across genetic subtypes, rather than limiting treatment to one mutation. The platform is being applied to retinitis pigmentosa, Stargardt disease and geographic atrophy secondary to dry age-related macular degeneration.
The lead ocular candidates are designed as one-time subretinal gene therapies, aiming for durable benefit from a single administration.
Ocugen’s Gene-Agnostic Bet on Broad RP CoverageOCU400 is the company’s phase III retinitis pigmentosa program and is positioned as gene-agnostic. Retinitis pigmentosa is linked to mutations in more than 100 genes, while the company notes that the only approved gene therapy targets one mutation that represents roughly 1% to 2% of patients.
OCU400 is intended to treat multiple gene mutations with a one-time subretinal injection, which Ocugen believes could translate into a therapeutic option for 98% to 99% of retinitis pigmentosa patients.
Enrollment in the phase III liMeliGhT study is complete at 140 patients, and top-line data are expected in the first quarter of 2027. The FDA has granted orphan drug designation to OCU400 for retinitis pigmentosa.
OCGN Stargardt Program and the Push Toward Mid-2027 BLAOCU410ST is being developed as a one-time gene therapy for Stargardt disease, an area where Ocugen notes there are no FDA-approved treatments.
Enrollment and dosing in the phase II/III GARDian3 confirmatory study were completed in April 2026. Top-line data are expected in the second quarter of 2027, with a biologics license application filing planned for mid-2027.
Ocugen has summarized earlier phase I results as supporting potential functional and structural benefits, raising the stakes for the pivotal package.
Ocugen’s GA Readouts and a Phase III Start in 2026OCU410 expands the platform into geographic atrophy. Twelve-month top-line data from the phase II ArMaDa study showed a statistically significant 31% reduction in lesion growth versus control at the intended medium dose, along with 27% ellipsoid zone preservation.
Ocugen plans to initiate a registrational phase III study in the third quarter of 2026, with the medium dose selected as the intended phase III dose and a potential biologics license application filing by 2028.
OCGN Pipeline Diversifiers From OCU200 to NeoCartOCU200, now in phase I, broadens the retinal portfolio beyond gene therapy into a biologic aimed at retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration.
NeoCart provides diversification outside ophthalmology. It is described as a phase III–ready regenerative cell therapy asset for knee cartilage repair.
Ocugen is also advancing an inhaled mucosal vaccine platform, and it states that the National Institute of Allergy and Infectious Diseases intends to initiate a phase I study for OCU500 in the second quarter of 2026.
As reference points in adjacent areas, REGENXBIO (RGNX - Free Report) is developing gene therapy candidates for retinal diseases, and Apellis Pharmaceuticals, which was recently acquired by Biogen (BIIB - Free Report) is associated with Syfovre in geographic atrophy.
Ocugen’s Biggest Execution Risks for This New ModalityOcugen’s risk profile is dominated by clinical and regulatory dependency. The company has no approved products and continues to burn cash, leaving results-driven volatility as a defining feature of the story.
Financing is another pressure point. Ocugen’s capital structure includes a May 2026 offering of 6.75% convertible senior notes due 2034, and the convertible structure adds potential share dilution if converted.
Validation for the emerging-trend thesis comes down to clean execution into 2026 registrational activity and strong, interpretable 2027 readouts across retinitis pigmentosa and Stargardt disease, with geographic atrophy progressing on its stated phase III and filing path.
OCGN’s Zacks RankOcugen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A month has gone by since the last earnings report for Ocugen (OCGN - Free Report) . Shares have lost about 10.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Ocugen due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Ocugen, Inc. before we dive into how investors and analysts have reacted as of late.
Q1 Loss Wider Than Expected, Sales Beat EstimatesOcugen incurred a loss of 6 cents per share in the first quarter of 2026, wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents.
Ocugen’s total revenues rose 3.5% year over year to $1.5 million in the first quarter, beating the Zacks Consensus Estimate of $1 million.
The company’s top line currently comprises only collaboration revenues
Q1 Results in DetailOcugen’s operating expenses increased during the quarter as the company accelerated clinical development and commercial preparation activities.
Research and development expenses were $11.3 million, up 18.1% from the year-ago quarter’s level. General and administrative expenses totaled $8.1 million, up 25.8% year over year.
The company raised $37.5 million in gross proceeds during the first quarter of 2026, including $15 million from investors exercising their warrants. As a result, its cash, cash equivalents, and restricted cash increased to $32.2 million as of March 31, 2026, up from $18.9 million at the end of 2025.
Following the $115 million offering of convertible senior notes, the company expects to have approximately $112.1 million in cash, cash equivalents, and restricted cash when the transaction closes, which includes the Avenue debt payoff.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in fresh estimates.
The consensus estimate has shifted 6.25% due to these changes.
VGM ScoresAt this time, Ocugen has a subpar Growth Score of D, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Ocugen has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerOcugen is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Axsome Therapeutics (AXSM - Free Report) , a stock from the same industry, has gained 4.9%. The company reported its results for the quarter ended March 2026 more than a month ago.
Axsome reported revenues of $191.2 million in the last reported quarter, representing a year-over-year change of +57.4%. EPS of -$1.26 for the same period compares with -$0.80 a year ago.
Axsome is expected to post a loss of $0.83 per share for the current quarter, representing a year-over-year change of +9.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -15.5%.
Axsome has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
